Navidea Biopharmaceuticals Stock Debt To Equity
| NAVBDelisted Stock | USD 0.1 0.01 9.45% |
Navidea Biopharmaceuticals fundamentals help investors to digest information that contributes to Navidea Biopharmaceutica's financial success or failures. It also enables traders to predict the movement of Navidea Pink Sheet. The fundamental analysis module provides a way to measure Navidea Biopharmaceutica's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Navidea Biopharmaceutica pink sheet.
Navidea |
Navidea Biopharmaceuticals Company Debt To Equity Analysis
Navidea Biopharmaceutica's Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current Navidea Biopharmaceutica Debt To Equity | 1.20 % |
Most of Navidea Biopharmaceutica's fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Navidea Biopharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
CompetitionAccording to the company disclosure, Navidea Biopharmaceuticals has a Debt To Equity of 1.199%. This is 97.76% lower than that of the Biotechnology sector and 93.81% lower than that of the Health Care industry. The debt to equity for all United States stocks is 97.54% higher than that of the company.
Navidea Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Navidea Biopharmaceutica's direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Navidea Biopharmaceutica could also be used in its relative valuation, which is a method of valuing Navidea Biopharmaceutica by comparing valuation metrics of similar companies.Navidea Biopharmaceutica is currently under evaluation in debt to equity category among its peers.
Navidea Fundamentals
| Return On Equity | -11.0 | ||||
| Return On Asset | -1.22 | ||||
| Current Valuation | 3.5 M | ||||
| Shares Outstanding | 100.08 M | ||||
| Shares Owned By Insiders | 35.43 % | ||||
| Shares Owned By Institutions | 1.50 % | ||||
| Number Of Shares Shorted | 2.69 M | ||||
| Price To Earning | 0.53 X | ||||
| Price To Book | 8.16 X | ||||
| Price To Sales | 84.14 X | ||||
| Revenue | 65.65 K | ||||
| Gross Profit | (119.3 K) | ||||
| EBITDA | (14.05 M) | ||||
| Net Income | (15.18 M) | ||||
| Cash And Equivalents | 328.01 K | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 2.43 M | ||||
| Debt To Equity | 1.20 % | ||||
| Current Ratio | 0.22 X | ||||
| Book Value Per Share | (0.01) X | ||||
| Cash Flow From Operations | (8.99 M) | ||||
| Short Ratio | 0.52 X | ||||
| Earnings Per Share | (0.39) X | ||||
| Target Price | 5.0 | ||||
| Number Of Employees | 11 | ||||
| Beta | 1.5 | ||||
| Market Capitalization | 8.04 M | ||||
| Total Asset | 4.37 M | ||||
| Retained Earnings | (388 M) | ||||
| Working Capital | (6.74 M) | ||||
| Current Asset | 12.58 M | ||||
| Current Liabilities | 6.18 M | ||||
| Net Asset | 4.37 M |
About Navidea Biopharmaceutica Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Navidea Biopharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Navidea Biopharmaceutica using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Navidea Biopharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Other Consideration for investing in Navidea Pink Sheet
If you are still planning to invest in Navidea Biopharmaceutica check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Navidea Biopharmaceutica's history and understand the potential risks before investing.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |